An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Decitabine (Primary) ; Decitabine (Primary) ; Sabatolimab (Primary) ; Spartalizumab (Primary) ; Venetoclax (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
Most Recent Events
- 28 Feb 2025 Planned End Date changed from 5 Nov 2025 to 14 Feb 2028.
- 28 Feb 2025 Planned primary completion date changed from 5 Nov 2025 to 14 Feb 2028.
- 14 Feb 2025 Planned End Date changed from 14 Feb 2028 to 5 Nov 2025.